Overview
Status
Active
Registry date
2004-10-14
Share capital
50,000.00 PLN
Registered address
Pułtuska 8, 61-052 Poznań, Poland
Electronic delivery address
AE:PL-25630-20415-HABGI-32
Financials
Revenue history (in k)
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 90 days for 2021).
- 202521/07/2026
- 202414/07/2025
- 202323/06/2024
- 202214/07/2023
- 202113/10/2022
- 202012/10/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 4.31mMedianUSD 1.92mAverageUSD 5.20m
Net profit
This companyUSD -5.24kMedianUSD 20.66kAverageUSD 86.55k
Operating costs
This companyUSD 4.25mMedianUSD 1.88mAverageUSD 5.04m
Assets
This companyUSD 806.55kMedianUSD 544.32kAverageUSD 1.76m
Industry
National Health Fund (NFZ) contracts
PRO Pharma has been an NFZ healthcare provider since 2023. In 2026 it is performing 4 contracts with a total value of USD 229.61. All its contracts were worth USD 744.20 in total.
NFZ contract value by year (USD)
| Type of care | NFZ branch | Contracts | Value in 2026 |
|---|---|---|---|
| Pilot programmes | wielkopolskie | 3 | USD 229.61 |
| Other services provided in pharmacies | wielkopolskie | 1 | USD 0.00 |
Authorized Representatives
Katarzyna Kulczycka Kałużna – President of the Management Board
Marcin Kałużny – Vice President of the Management Board
Manner of representation
Independent representation.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Marcin Kałużnyage 49 | 250 | $6,753.11 | 50% |
Rodzina Kałużnych Fundacja Rodzinna w Organizacji | 249 | $6,726.09 | 49.8% |
Others | 1 | $27.01 | 0.2% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 7,007PLN 7,007 |
Public aid
15 public aid cases recorded, with a total value of $244,467.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 8, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $4,899$4,899 | Wielkopolska Agencja Rozwoju Przedsiębiorczości sp. z o.o. | |
| Jan 8, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $4,818$4,818 | Wielkopolska Agencja Rozwoju Przedsiębiorczości sp. z o.o. | |
| Dec 4, 2023 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $2,285$2,285 | Prezes Banku Gospodarstwa Krajowego |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Przedsiębiorstwo Produkcyjno-Handlowe Apimexsp. z o.o. | $16,601,428.28 | apimex.pl | ||
| Modrzewscysp. j. | $5,602,358.99 | aptekacentrum.lublin.pl | ||
| Ms-Pharmsp. z o.o. + limited partnership | $4,619,501.46 | mspharm.pl | ||
| Farmjug Agsp. z o.o. | $4,213,734.86 | farmjug.pl | ||
| MagmaxS.A. | $4,200,912.15 | magmaxsa.pl | ||
| Adpharmasp. z o.o. | $4,026,799.19 | adamed.com | ||
| Alfa Pharm - Małgorzata Janusik, Jarosław Janusiksp. j. | $3,414,382.70 | aptekazielona.com.pl | ||
| Gold Lionsp. z o.o. | $1,669,649.21 | goldlion.pl | ||
| Grupa Aptekarska Kujałowiczsp. j. | $1,452,484.91 | wga.pl | ||
| Rutkiewicz I Wspólnicysp. j. | – | aptekapoznan.com |
Change history
| Date | Event | |
|---|---|---|
| 2019-07-08 | Switch to PKD 2007 (19 PKD 2004 codes → 10 PKD 2007 codes) | |
| 2012-02-24 | Address change (Małachowskiego 31, 61-129, Poznań → Pułtuska 8, 61-052, Poznań) | |
| 2004-10-14 | Entered in the register |
FAQ
The main business activity of PRO Pharma focuses on dispensing chemist in specialised stores.
The company was registered in the Polish National Court Register (KRS) on October 14, 2004.
The headquarters is located at: Pułtuska 8, 61-052 Poznań.
The share capital of the company is PLN 50,000 (approx. $13,506).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company generated total revenue of $4,311,044, representing an increase of 7.4% compared to 2024.
No, the company recorded a net loss of $5,244 in 2025.
The largest operating cost category falls under cost of goods and materials sold. This category amounted to $3,250,649 in 2025, representing 77% of all operating expenses.
Last updated: 2026-07-21
